Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Aubagio | Teriflunomide | Multiple sclerosis, relapsing-remitting | Do not list at the submitted price | Complete | ||
| Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete | ||
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete | ||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete | ||
| Elelyso | Taliglucerase alfa | Gaucher disease | Do not list | Complete | ||
| Otezla | Apremilast | Plaque psoriasis | Do not list | Complete | ||
| Constella | Linaclotide | Irritable bowel syndrome with constipation | Do not list | Complete | ||
| Dymista | Azelastine HCl and fluticasone propionate | Seasonal allergic rhinitis | Do not list | Complete |
Last Updated : May 12, 2024